AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

Article

The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research.

The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research. The AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research is given to a scientist residing in any country in the world for his or her seminal contributions to the field of cancer prevention. Such investigations must have been conducted in basic, translational, clinical, epidemiological, or behavioral science in cancer prevention research. Further, these studies must have had not only a major impact on the field, but must also have stimulated new directions in this important area.

The recipient of the Award will receive a $5,000 honorarium and present a 50-minute lecture at the 8th Annual AACR International Conference on Frontiers in Cancer Prevention Research. The Conference will be held December 6-9, 2009, at the Hilton Americas, Houston, TX.

The nomination deadline is Friday, July 31, 2009.

For more information: http://www.aacr.org/home/scientists/scientific-achievement-awards/prevent-cancer-award.aspx

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content